722 related articles for article (PubMed ID: 16649846)
1. Navigating patients and caregivers through the course of Alzheimer's disease.
Aupperle PM
J Clin Psychiatry; 2006; 67 Suppl 3():8-14; quiz 23. PubMed ID: 16649846
[TBL] [Abstract][Full Text] [Related]
2. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
Tariot PN
J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
[TBL] [Abstract][Full Text] [Related]
3. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
Beier MT
Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
[TBL] [Abstract][Full Text] [Related]
4. Practical treatment strategies for patients with Alzheimer's disease.
Christensen DD; Lin P
J Fam Pract; 2007 Dec; 56(12 Suppl New):S17-23. PubMed ID: 18664338
[TBL] [Abstract][Full Text] [Related]
5. Early diagnosis and management of Alzheimer's disease.
Duncan BA; Siegal AP
J Clin Psychiatry; 1998; 59 Suppl 9():15-21. PubMed ID: 9720482
[TBL] [Abstract][Full Text] [Related]
6. Impact of donepezil hydrochloride on the care burden of family caregivers of patients with Alzheimer's disease.
Hashimoto M; Yatabe Y; Kaneda K; Honda K; Ikeda M
Psychogeriatrics; 2009 Dec; 9(4):196-203. PubMed ID: 20377821
[TBL] [Abstract][Full Text] [Related]
7. [Impact of music therapy on anxiety and depression for patients with Alzheimer's disease and on the burden felt by the main caregiver (feasibility study)].
Guetin S; Portet F; Picot MC; Defez C; Pose C; Blayac JP; Touchon J
Encephale; 2009 Feb; 35(1):57-65. PubMed ID: 19250995
[TBL] [Abstract][Full Text] [Related]
8. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
Pomara N; Ott BR; Peskind E; Resnick EM
Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
[TBL] [Abstract][Full Text] [Related]
9. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
Campanozzi MD; Casali E; Neviani F; Martini E; Neri M
Arch Gerontol Geriatr; 2007; 44 Suppl 1():91-6. PubMed ID: 17317439
[TBL] [Abstract][Full Text] [Related]
11. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
Feldman HH; Schmitt FA; Olin JT;
Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
[TBL] [Abstract][Full Text] [Related]
12. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
[TBL] [Abstract][Full Text] [Related]
13. Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council.
Fillit H; Cummings J
Manag Care Interface; 2000 Jan; 13(1):51-6. PubMed ID: 10747691
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
Bullock R
Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.
Waldemar G; Hyvärinen M; Josiassen MK; Kørner A; Lehto H; Wetterberg P
Int J Geriatr Psychiatry; 2008 Sep; 23(9):979-81. PubMed ID: 18229874
[No Abstract] [Full Text] [Related]
16. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
[TBL] [Abstract][Full Text] [Related]
17. Cognitive function and caregiver burden: predictive factors for eating behaviour disorders in Alzheimer's disease.
Rivière S; Gillette-Guyonnet S; Andrieu S; Nourhashemi F; Lauque S; Cantet C; Salva A; Frisoni G; Vellas B
Int J Geriatr Psychiatry; 2002 Oct; 17(10):950-5. PubMed ID: 12325056
[TBL] [Abstract][Full Text] [Related]
18. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
Grossberg GT; Pejović V; Miller ML; Graham SM
Dement Geriatr Cogn Disord; 2009; 27(2):164-72. PubMed ID: 19194105
[TBL] [Abstract][Full Text] [Related]
19. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's disease: a review of recent developments.
Salawu FK; Umar JT; Olokoba AB
Ann Afr Med; 2011; 10(2):73-9. PubMed ID: 21691010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
